Dehydro-α-lapachone, a plant product with antivascular activity

Proceedings of the National Academy of Sciences of the United States of America

Volumn 108, Issue 28, 2011, Pages 11596-11601

  Garkavtsev, Igor ^a   Chauhan, Vikash P ^a,b   Wong, Hon Kit ^a   Mukhopadhyay, Arpita ^a   Glicksman, Marcie A ^c   Peterson, Randall T ^a   Jain, Rakesh K ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD UNIVERSITY   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Angiogenesis; Drug discovery

Indexed keywords

DEHYDROLAPACHONE; PLANT EXTRACT; RAC1 PROTEIN; RHO GUANINE NUCLEOTIDE BINDING PROTEIN; UNCLASSIFIED DRUG; VASCULAR TARGETING AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL ADHESION; CONTROLLED STUDY; DRUG DETERMINATION; EMBRYO; FEMALE; HIGH THROUGHPUT SCREENING; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TARGET CELL; TRANSGENIC ANIMAL; UBIQUITINATION; VASCULAR ENDOTHELIUM; ZEBRA FISH;

ANGIOGENESIS INHIBITORS; ANIMALS; ANIMALS, GENETICALLY MODIFIED; CELL ADHESION; CELL LINE, TUMOR; CELLS, CULTURED; ENDOTHELIAL CELLS; FEMALE; GREEN FLUORESCENT PROTEINS; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, SCID; NAPHTHOQUINONES; PLANTS, MEDICINAL; RAC1 GTP-BINDING PROTEIN; TABEBUIA; ZEBRAFISH;

DANIO RERIO; MUS;

EID: 79960983484     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1104225108     Document Type: Article

References (35)

1. Carmeliet P, Jain RK (2011) Molecular mechanisms and clinical applications of angiogenesis. Nature 473:298-307.
2. Folkman J (2007) Angiogenesis: An organizing principle for drug discovery? Nat Rev Drug Discov 6:273-286.
3. Chung AS, Lee J, Ferrara N (2010) Targeting the tumour vasculature: Insights from physiological angiogenesis. Nat Rev Cancer 10:505-514.
4. Nagy JA, Chang SH, Dvorak AM, Dvorak HF (2009) Why are tumour blood vessels abnormal and why is it important to know? Br J Cancer 100:865-869.
5. Olsson AK, Dimberg A, Kreuger J, Claesson-Welsh L (2006) VEGF receptor signalling - in control of vascular function. Nat Rev Mol Cell Biol 7:359-371.
6. Bergers G, Hanahan D (2008) Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 8:592-603.
7. Jain RK, et al. (2009) Biomarkers of response and resistance to antiangiogenic therapy. Nat Rev Clin Oncol 6:327-338.
8. Carmeliet P, et al. (1999) Targeted deficiency or cytosolic truncation of the VE-cadherin gene in mice impairs VEGF-mediated endothelial survival and angiogenesis. Cell 98:147-157. (Pubitemid 29344903)
9. Corada M, et al. (1999) Vascular endothelial-cadherin is an important determinant of microvascular integrity in vivo. Proc Natl Acad Sci USA 96:9815-9820. (Pubitemid 29398815)
10. Jain RK (2005) Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy. Science 307:58-62.
11. Dejana E (2004) Endothelial cell-cell junctions: Happy together. Nat Rev Mol Cell Biol 5:261-270.
12. Hashizume H, et al. (2000) Openings between defective endothelial cells explain tumor vessel leakiness. Am J Pathol 156:1363-1380. (Pubitemid 30660013)
13. Hobbs SK, et al. (1998) Regulation of transport pathways in tumor vessels: Role of tumor type and microenvironment. Proc Natl Acad Sci USA 95:4607-4612. (Pubitemid 28207960)
14. Corada M, et al. (2002) A monoclonal antibody to vascular endothelial-cadherin inhibits tumor angiogenesis without side effects on endothelial permeability. Blood 100:905-911. (Pubitemid 34832616)
15. Gumbiner BM (2005) Regulation of cadherin-mediated adhesion in morphogenesis. Nat Rev Mol Cell Biol 6:622-634.
16. Borisy GG, Svitkina TM (2000) Actin machinery: Pushing the envelope. Curr Opin Cell Biol 12:104-112. (Pubitemid 30095276)
17. Li CJ, Averboukh L, Pardee AB (1993) beta-Lapachone, a novel DNA topoisomerase I inhibitor with a mode of action different from camptothecin. J Biol Chem 268: 22463-22468. (Pubitemid 23318296)
18. Planchon SM, et al. (1995) Beta-lapachone-mediated apoptosis in human promyelocytic leukemia (HL-60) and human prostate cancer cells: A p53-independent response. Cancer Res 55:3706-3711.
19. Huang CC, Lawson ND, Weinstein BM, Johnson SL (2003) reg6 is required for branching morphogenesis during blood vessel regeneration in zebrafish caudal fins. Dev Biol 264:263-274. (Pubitemid 37393462)
20. Whitehead GG, Makino S, Lien CL, Keating MT (2005) fgf20 is essential for initiating zebrafish fin regeneration. Science 310:1957-1960. (Pubitemid 43005989)
21. Nechiporuk A, Keating MT (2002) A proliferation gradient between proximal and msxb-expressing distal blastema directs zebrafish fin regeneration. Development 129:2607-2617. (Pubitemid 34874245)
22. Brown E, et al. (2003) Dynamic imaging of collagen and its modulation in tumors in vivo using second-harmonic generation. Nat Med 9:796-800. (Pubitemid 36749232)
23. Garkavtsev I, et al. (2004) The candidate tumour suppressor protein ING4 regulates brain tumour growth and angiogenesis. Nature 428:328-332. (Pubitemid 38418804)
24. Vakoc BJ, et al. (2009) Three-dimensional microscopy of the tumor microenvironment in vivo using optical frequency domain imaging. Nat Med 15:1219-1223.
25. Anderson JM, Van Itallie CM (2008) Tight junctions. Curr Biol 18:R941-R943.
26. Miyoshi J, Takai Y (2005) Molecular perspective on tight-junction assembly and epithelial polarity. Adv Drug Deliv Rev 57:815-855. (Pubitemid 40488106)
27. Tzima E (2006) Role of small GTPases in endothelial cytoskeletal dynamics and the shear stress response. Circ Res 98:176-185.
28. Tsukita S, Furuse M, Itoh M (2001) Multifunctional strands in tight junctions. Nat Rev Mol Cell Biol 2:285-293. (Pubitemid 33676971)
29. Ridley AJ (2006) Rho GTPases and actin dynamics in membrane protrusions and vesicle trafficking. Trends Cell Biol 16:522-529.
30. Wojciak-Stothard B, Ridley AJ (2002) Rho GTPases and the regulation of endothelial permeability. Vascul Pharmacol 39:187-199. (Pubitemid 37492962)
31. Reinstein E, Ciechanover A (2006) Narrative review: Protein degradation and human diseases: The ubiquitin connection. Ann Intern Med 145:676-684. (Pubitemid 46768844)
32. Bence NF, Sampat RM, Kopito RR (2001) Impairment of the ubiquitin-proteasome system by protein aggregation. Science 292:1552-1555. (Pubitemid 32493425)
33. Wong HK, et al. (2008) Blocking acid-sensing ion channel 1 alleviates Huntington's disease pathology via an ubiquitin-proteasome system-dependent mechanism. Hum Mol Genet 17:3223-3235.
34. He KL, et al. (2008) Endothelial cell annexin A2 regulates polyubiquitination and degradation of its binding partner S100A10/p11. J Biol Chem 283:19192-19200.
35. Jain RK, Munn LL, Fukumura D (2011) Transparent Window Models and Intravital Microscopy: Imaging Gene Expression, Physiological Function and Therapeutic Effects in Tumors. Tumor Models in Cancer Research, ed Teicher BA (Humana, New York), pp 641-681.